A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
The purpose of this study is to determine how well the combination of therapy of talimogene laherparepvec (T-VEC) and pembrolizumab works in the treatment of patients with sarcoma.
Sarcoma|Epithelioid Sarcoma|Cutaneous Angiosarcoma
DRUG: Talimogene Laherparepvec (T-VEC)|DRUG: Pembrolizumab
best objective response rate, (complete response + partial response) RECIST 1.1, 24 weeks
The purpose of this study is to determine how well the combination of therapy of talimogene laherparepvec (T-VEC) and pembrolizumab works in the treatment of patients with sarcoma.